Viral Protein Patents (Class 536/23.72)
-
Patent number: 8835620Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal.Type: GrantFiled: January 12, 2009Date of Patent: September 16, 2014Assignee: VGX Pharmaceuticals, LLCInventors: Mathura P. Ramanathan, Niranjan Sardesai
-
Publication number: 20140255442Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.Type: ApplicationFiled: May 19, 2014Publication date: September 11, 2014Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Kim BURGARD, Jeremy KROLL, Sarah M. LAYTON, Volker OHLINGER, Francois-Xavier ORVEILLON, Stefan PESCH, Michael Dennis PIONTKOWSKI, Michael B. ROOF, Philip UTLEY, Eric Martin VAUGHN
-
Publication number: 20140256583Abstract: The invention relates to human endogenous retrovirus env (HERV-WL) polypeptides, nucleotide sequences, HERV-WL antibodies, methods to detect cancer, and methods to determine the effectiveness of the treatment of cancer.Type: ApplicationFiled: March 5, 2014Publication date: September 11, 2014Applicant: Rutgers, The State University of New JerseyInventors: Vincent K. Tsiagbe, Yu Li
-
Patent number: 8828408Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV VP13/14 polypeptides.Type: GrantFiled: March 15, 2013Date of Patent: September 9, 2014Assignees: Vical Incorporated, The University of WashingtonInventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
-
Patent number: 8829174Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1 a/1 b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.Type: GrantFiled: October 29, 2008Date of Patent: September 9, 2014Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David B Weiner, Krystle A. Lang Kuhs, Jian Yan, Ruxandra Draghia-Akli, Amir Khan
-
Patent number: 8828406Abstract: Described herein are chimeric influenza virus gene segments and nucleic acid sequences encoding such chimeric influenza virus gene segments. A chimeric influenza virus gene segment described herein comprises packaging signals found in the non-coding and coding regions of one type of influenza virus gene segment and an open reading frame of a different type of influenza virus gene segment or fragment thereof. Also described herein are recombinant influenza viruses comprising two or more chimeric influenza virus gene segments and the use of such viruses in the prevention and/or treatment of influenza virus disease.Type: GrantFiled: July 29, 2010Date of Patent: September 9, 2014Assignee: Icahn School of Medicine at Mount SinaiInventors: Adolfo Garcia-Sastre, Peter Palese, Qinshan Gao
-
Patent number: 8828407Abstract: The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the S2 subunit from a coronavirus strain with extended tissue tropism, such that a virus comprising the chimaeric S protein has extended tissue tropism. The present invention also provides a virus comprising such a chimaeric S protein.Type: GrantFiled: July 5, 2010Date of Patent: September 9, 2014Assignee: The Pirbright InstituteInventors: Paul Britton, Erica Bickerton, Maria Armesto
-
Patent number: 8828933Abstract: Disclosed are viral proteins associated with Human Immunodeficiency Virus (HIV) infections and mutants thereof, particularly, mutant Tat proteins capable of modulating multiple steps of the HIV-1 replication cycle. Also provided are methods of using the mutant Tat proteins, and pharmaceutical compositions comprising the same, for prevention and treatment of HIV-1 infections, and/or symptoms associated therewith.Type: GrantFiled: November 9, 2011Date of Patent: September 9, 2014Assignee: The Council of the Queensland Institute of Medical ResearchInventor: David Harrich
-
Publication number: 20140248301Abstract: The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable for use in such a method.Type: ApplicationFiled: December 13, 2013Publication date: September 4, 2014Inventors: Barton F. Haynes, Hua-Xin Liao, Li-Hua Ping, Ronald Swanstrom, Beatrice H. Hahn, George M. Shaw
-
Publication number: 20140248314Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.Type: ApplicationFiled: May 14, 2012Publication date: September 4, 2014Applicant: NOVARTIS AGInventors: Kurt Swanson, Andrea Carfi
-
Publication number: 20140248311Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.Type: ApplicationFiled: July 5, 2012Publication date: September 4, 2014Applicants: DUKE UNIVERSITY, U.S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Jerome Kim, Stephen Harrison, Barton F. Haynes, Georgia D. Tomaras, Nelson Michael
-
Patent number: 8822665Abstract: The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress.Type: GrantFiled: April 2, 2010Date of Patent: September 2, 2014Assignees: Institut Pasteur, Thomas Jefferson UniversityInventors: Christophe Prehaud, Monique Lafon, Matthias Johannes Schnell
-
Patent number: 8821890Abstract: The present invention is directed to compositions and methods for enhancing the immune response of a human in need of protection against influenza virus (IV) infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof, or a protein encoded thereby. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.Type: GrantFiled: September 30, 2011Date of Patent: September 2, 2014Assignee: Vical IncorporatedInventors: Catherine J. Luke, Adrian Vilalta, Mary K. Wloch, Thomas G. Evans, Andrew J. Geall, Gretchen S. Jimenez
-
Publication number: 20140234262Abstract: At least one novel virus capable of infecting crazy ants (Nylanderia fulva) is isolated, along with polynucleotide sequences and amino acid sequences of the virus. The virus is capable of be used as a biopesticide to control populations of crazy ants.Type: ApplicationFiled: February 7, 2014Publication date: August 21, 2014Inventors: Steven M. Valles, David H. Oi
-
Publication number: 20140234355Abstract: The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen.Type: ApplicationFiled: December 19, 2013Publication date: August 21, 2014Applicant: Zoetis LLCInventors: Gregory Paul NITZEL, Robert Gerard Ankenbauer, Jay Gregory Calvert, Donna Steuerwald Dunyak, Jacqueline Gayle Marx, Nancee Lois Oien, Douglas Steven Pearce, Mira Ivanova Stoeva, James Richard Thompson
-
Publication number: 20140234274Abstract: The present invention provides methods of achieving directed evolution of viruses by in vivo screening or “panning” to identify viruses comprising scrambled AAV capsids having characteristics of interest, e.g., tropism profile and/or neutralization profile (e.g., ability to evade neutralizing antibodies). The invention also provides scrambled AAV capsids and virus particles comprising the same.Type: ApplicationFiled: January 17, 2014Publication date: August 21, 2014Applicant: University of North Carolina at Chapel HillInventors: Xiao Xiao, Lin Yang
-
Publication number: 20140234354Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5B (PPV5B) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.Type: ApplicationFiled: March 13, 2013Publication date: August 21, 2014Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventors: Arun V. IYER, Dianna M. Murphy JORDAN, Abby Rae PATTERSON, Michael B. ROOF, Eric Martin VAUGHN, Joseph Gilbert VICTORIA, Callie Ann VISEK
-
Publication number: 20140237631Abstract: Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof.Type: ApplicationFiled: March 31, 2014Publication date: August 21, 2014Applicants: KIMRON VETERINARY INSTITUTE, INSTITUT PASTEURInventors: Despres Philippe, Vincent Deubel, Jean-Louis Guenet, Marie-Therese Drouet, Mertyn Malkinson, Caroline Banet, Marie-Pascale Frenkiel, Marie-Pierre Courageot, Fasseli Coulibaly, Adeline Catteau, Marie Flamand, Patrick Weber, Pierre-Emmanuel Ceccaldi
-
Publication number: 20140234943Abstract: The document provides nucleic acids, polypeptides, and viruses containing nucleic acids and/or polypeptides. The document also provides methods for using viruses to treat cancer patients. Specifically, the document provides nucleic acid molecules encoding viral hemagglutinin (H) polypeptides, viral H polypeptides, and viruses containing nucleic acids and/or H polypeptides. Such viruses are useful for vaccinations and for treating cancer patients as the viruses are not shed.Type: ApplicationFiled: April 10, 2014Publication date: August 21, 2014Applicant: Mayo Foundation for Medical Education and ResearchInventors: Roberto Cattaneo, Vincent H.J. Leonard
-
Publication number: 20140227230Abstract: An object of the present invention is to provide a novel method of controlling TYLCV whereby the infection cycle of TYLCV can be broken. The present invention provides a novel virus that is not transmitted by an insect vector as a tomato yellow leaf curl virus. The present invention also provides a method of controlling a tomato yellow leaf curl disease and a method of preventing transmission of a yellow leaf curl virus by using a tomato yellow leaf curl virus not transmitted by an insect vector.Type: ApplicationFiled: February 3, 2012Publication date: August 14, 2014Applicants: UTSUNOMIYA UNIVERSITY, KIKKOMAN CORPORATIONInventors: Hiroki Atarashi, Toshiro Inoue, Haruki Sayama, Hisashi Nishigawa, Tamotsu Murai, Tomohide Natsuaki
-
Publication number: 20140227765Abstract: Certain embodiments are directed to Negevirus and their polynucleotides and polypeptides.Type: ApplicationFiled: November 21, 2013Publication date: August 14, 2014Applicant: The Board of Regents of the University of Texas SystemInventors: Farooq Nasar, Rodion V. Gorchakov, Andrew D. Haddow, Robert B. Tesh, Hilda Guzman, Scott C. Weaver
-
Publication number: 20140220107Abstract: The instant application provides methods and related compositions pertaining to novel HIV envelope proteins. In some embodiments, the invention relates to methods and compositions for the preparation, production, and administration of isolated novel HIV envelope nucleic acid and protein sequences suitable, for example, as vaccines against HIV.Type: ApplicationFiled: April 25, 2012Publication date: August 7, 2014Applicants: ADVANCED BIOSCIENCE LABORATORIES, INC., HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, THE GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARYInventors: Vaniambadi Kalyanaraman, Stephen Whitney, Thomas C. Vancott, Victoria Polonis, Carl Alving, Gary R. Matyas, Mangala Rao, Mary Marovich, Francine McCutchan, Sodsai Tovanabutra, Eric Sanders-Buell
-
Publication number: 20140219918Abstract: The present invention provides a foot-and-mouth diseases virus (FMDV) VP1 capsid protein which comprises an entity of interest (EOI). The EOI sequence may, for example, be an epitope tag, an immunomodulatory molecule or a target molecule. The present invention also provides an FMDV vaccine which comprises such a VP1 capsid protein and its use to prevent FMD.Type: ApplicationFiled: June 26, 2012Publication date: August 7, 2014Applicant: THE PIRBRIGHT INSTITUTEInventors: Julian Seago, Nicholas Juleff
-
Publication number: 20140221636Abstract: The present invention provides a bovine adeno-associated virus (BAAV) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the BAAV vectors and particles.Type: ApplicationFiled: February 13, 2014Publication date: August 7, 2014Applicant: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: John A. Chiorini, Michael Schmidt, Ioannis Bossis, Giovanni Di Pasquale
-
Publication number: 20140220636Abstract: The invention encompasses phage ?mru including phage induction, phage particles, and the phage genome. Also encompassed are phage polypeptides, as well as polynucleotides which encode these polypeptides, expression vectors comprising these polynucleotides, and host cells comprising these vectors. The invention further encompasses compositions and methods for detecting, targeting, permeabilising, and inhibiting microbial cells, especially methanogen cells, using the disclosed phage, polypeptides, polynucleotides, expression vectors, or host cells.Type: ApplicationFiled: October 25, 2013Publication date: August 7, 2014Applicant: Pastoral Greenhouse Gas Research LimitedInventors: Eric Heinz Altermann, Graeme Trevor Attwood, Sinead Christine Leahy, William John Kelly, Robert Starr Ronimus, Dong Li, Zhanhao Kong, Linley Rose Schofield, Debjit Dey, Catherine Mary Totill, Carrie Sang, Christina Diane Moon, Petrus Hendricus Janssen
-
Patent number: 8795676Abstract: The present invention discloses a codon-optimized gene encoding major capsid protein L1 of human papilloma virus, which is capable, after transduced into a yeast cell, of efficiently expressing the major capsid protein L1 of human papilloma virus. The present invention also discloses an immunogenic macromolecule which is essentially produced by expression of said codon-optimized gene encoding the major capsid protein L1 of human papilloma virus in a yeast cell. The present invention further discloses the use of said immunogenic macromolecule and a composition comprising said immunogenic macromolecule.Type: GrantFiled: November 24, 2008Date of Patent: August 5, 2014Assignee: Shanghai Zerun Biotechnology Co., Ltd.Inventors: Gaoxia Zhang, Qiong Shen, Jianqiang Lei, Jingyu Yuan, Menghua Zhang, Qianli Zhang, Yinghua Xiong, Roger Wei, Ke Wu
-
Publication number: 20140212447Abstract: The present invention describes subunit vaccines containing Gn and Gc glycoproteins of the Rift Valley Fever Virus, including nucleic acids encoding such glycoproteins, host cells, vectors, and immunoreagents generated with the glycoproteins, methods of vaccination, methods of diagnosis, and kits.Type: ApplicationFiled: January 28, 2014Publication date: July 31, 2014Applicants: The United States Government as represented by the Secretary of Agriculture, KANSAS STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Juergen A. Richt, Bonto Faburay, William Wilson
-
Publication number: 20140205629Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: ApplicationFiled: March 28, 2014Publication date: July 24, 2014Applicant: AlphaVax, Inc.Inventors: Jon O. RAYNER, Jonathan F. SMITH, Bolyn HUBBY, Elizabeth A. REAP
-
Publication number: 20140205621Abstract: A new pantropic canine coronavirus (CCoV) strain, having reduced pathogenicity, and capable of eliciting an immune response, is described.Type: ApplicationFiled: June 26, 2012Publication date: July 24, 2014Inventors: Nicola Decaro, Vito Martella, Gabriella Elia, Canio Buonavoglia
-
Patent number: 8785411Abstract: The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3? LTR.Type: GrantFiled: July 18, 2011Date of Patent: July 22, 2014Assignee: University of Kansas Medical CenterInventor: Zhenqian Liu
-
Patent number: 8785596Abstract: Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.Type: GrantFiled: December 20, 2010Date of Patent: July 22, 2014Assignee: Abbott LaboratoriesInventors: John R. Hackett, Jr., Julie Yamaguchi, Alan M. Golden, Catherine A. Brennan, Robert K. Hickman, Sushil G. Devare
-
Patent number: 8778671Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.Type: GrantFiled: June 18, 2004Date of Patent: July 15, 2014Assignees: The United States of America, as represented by the Secretary of the Department of Health & Human Services, The Walter Reed Army Institute of ResearchInventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney, Jr.
-
Patent number: 8778351Abstract: The present invention relates to compositions that contain a chimeric papillomavirus virus-like particle (VLP) in combination with a DNA molecule encoding a protein or polypeptide epitope. The chimeric papillomavirus VLP is assembled from an L1 protein or polypeptide and a chimeric protein or polypeptide containing at least a portion of the L2 protein and a protein or polypeptide including an immunogenic epitope. The composition is useful for inducing an enhanced immune response against a pathogen or a tumor.Type: GrantFiled: August 30, 2007Date of Patent: July 15, 2014Assignee: University of RochesterInventors: Robert C. Rose, Christine Malboeuf, Young-Eun Ellen Lee
-
Patent number: 8779113Abstract: The invention provides a group of nucleic acid fragments, shown in the sequence listing, for prevention of HIV infection or AIDS and the usage thereof. In the invention, a series of RNA fragments, which are highly homogenous to all the published HIV gene sequences, were obtained by homology compare. The double-stranded RNA (dsRNA) derived from these fragments can effectively inhibit the expression of the HIV genes. The RNA transcribed by plasmid, also can suppress the expression of the HIV in the cell. After the adenovirus or associated virus which carry DNA corresponding above RNA infect the cell, the transcription dsRNA can inhibit the expression of the HIV genes.Type: GrantFiled: January 10, 2011Date of Patent: July 15, 2014Assignee: Beijing Solobio Genetechnology Company Ltd.Inventors: Zhiwen Zhou, Yuxia Feng, Conglin Zuo, Yuejuan Li
-
Publication number: 20140193450Abstract: The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the N- and C-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.Type: ApplicationFiled: June 11, 2012Publication date: July 10, 2014Applicant: BIOMAY AGInventors: Katarzyna Niespodziana, Margarete Focke-Tejkl, Susanne Vrtala, Srinita Banerjee, Kuan-Wei Chen, Milena Weber, Rudolf Valenta, Katharina Marth
-
Publication number: 20140193482Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.Type: ApplicationFiled: December 12, 2013Publication date: July 10, 2014Applicant: MODERNA THERAPEUTICS, INC.Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Susan Whoriskey, Ron Weiss
-
Publication number: 20140193448Abstract: The present invention relates to a recombinant DNA molecule encoding a mutated hemagglutinin protein, wherein the mutated hemagglutinin protein consists of the amino acid sequence of SEQ ID NO: 2 with one or more mutations at amino acid residue selecting from the group consisting of residue 83, 127, 138 and the combination thereof. The present invention also relates to a composition comprising the recombinant DNA molecule as described above and a pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant, or vehicle. The present invention further relates to a kit for prime-boost vaccination, comprising at least a composition comprising a recombinant DNA molecule as described above and at least a composition for the boost-vaccination comprising a recombinant hemagglutiinin protein or a virus-like particle, wherein the recombinant hemagglutiinin protein is the corresponding hemagglutiinin protein encoded by the recombinant DNA molecule.Type: ApplicationFiled: March 19, 2014Publication date: July 10, 2014Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Suh-Chin Wu, Shih-Chang Lin
-
Patent number: 8771702Abstract: The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin O (LLO) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The present invention also provides methods of utilizing recombinant proteins, peptides, nucleotide molecules, and vaccine vectors of the present invention to induce an immune response to a peptide of interest.Type: GrantFiled: June 23, 2008Date of Patent: July 8, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: Yvonne Paterson, Paulo Cesar Maciag
-
Patent number: 8771703Abstract: The present invention provides a recombinant soluble trimeric hemagglutinin (rHA) protein comprising a hemagglutinin ectodomain and an oligomerization domain. The rHA is produced as a soluble homotrimer, and may further comprises a signal peptide and/or an endoplasmic reticulum (ER) retention signal. The invention is also directed to nucleic acids encoding the rHA of the invention, as well as vectors and chimeric constructs comprising the nucleic acid. Methods of producing the rHA are also provided. The rHA described herein may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.Type: GrantFiled: July 7, 2009Date of Patent: July 8, 2014Assignee: Medicago Inc.Inventors: Manon Couture, Nathalie Landry, Louis-Philippe Vezina, Michéle Dargis
-
Patent number: 8772256Abstract: The present invention features immunogenic compositions comprising codon modified genes that encode viral proteins and/or glycoproteins or fragments. The immunogenic compositions of the invention are useful in various methods of treatment, such as preventing or treating viral infection. Also provided in the present invention are kits and instructions for use.Type: GrantFiled: November 30, 2007Date of Patent: July 8, 2014Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Barney S. Graham, Teresa R. Johnson
-
Publication number: 20140186384Abstract: Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed.Type: ApplicationFiled: December 23, 2013Publication date: July 3, 2014Applicant: The Trustees of the University of PennsylvaniaInventors: David B. Weiner, Jian Yan
-
Publication number: 20140186382Abstract: The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above.Type: ApplicationFiled: February 10, 2014Publication date: July 3, 2014Applicant: Vical IncorporatedInventors: Gary G. HERMANSON, Andrew J. Geall, Mary Kopke Wloch
-
Patent number: 8765140Abstract: The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3? LTR.Type: GrantFiled: July 18, 2011Date of Patent: July 1, 2014Assignee: University of Kansas Medical CenterInventor: Zhenqian Liu
-
Patent number: 8765141Abstract: We have generated novel molecularly marked FMDV A24LL3DYR and A24LL3BPVKV3DYR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3Dpol and 3B proteins. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. The mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live A24LL3DYR. Cattle immunized with chemically inactivated vaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine. These vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.Type: GrantFiled: June 9, 2011Date of Patent: July 1, 2014Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: Aida E. Rieder, Luis L. Rodriguez, Jason R. Hollister, Sabena Uddowla
-
Publication number: 20140178855Abstract: Novel murine astroviruses, and methods of detecting the viruses are disclosed. Also disclosed are uses of the viruses and infected animals as model systems for discovery and development of vaccines and therapies for diseases caused by or associated with astrovirus infection, including human astrovirus-based diseases.Type: ApplicationFiled: August 1, 2013Publication date: June 26, 2014Applicant: WASHINGTON UNIVERSITYInventors: Herbert W. Virgin, David Wang, Joy Loh, Thad Stappenbeck, Guoyan Zhao, Larissa Thackray, Christine Yokoyama
-
Publication number: 20140170186Abstract: The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.Type: ApplicationFiled: January 31, 2012Publication date: June 19, 2014Applicant: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH....Inventors: Gary J. Nabel, Srinivas Rao, Wataru Akahata
-
Publication number: 20140170180Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.Type: ApplicationFiled: March 12, 2013Publication date: June 19, 2014Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventors: Arun V. IYER, Dianna M. Murphy JORDAN, Abby Rae PATTERSON, Michael B. ROOF, Eric Martin VAUGHN, Joseph Gilbert VICTORIA, Callie Ann VISEK
-
Publication number: 20140170187Abstract: The present invention is directed to mutant parvovirus VP1 unique region polypeptides, compositions comprising such polypeptides, methods of making such compositions, as well as methods for identifying the likely presence of parvovirus-neutralizing antibodies, and methods for assessing the functional immunogenicity of parvovirus vaccines and measuring a correlate of efficacy to assess a treatment for parvovirus infection.Type: ApplicationFiled: July 25, 2012Publication date: June 19, 2014Inventors: Ethan Settembre, Sumana Chandramouli
-
Publication number: 20140162319Abstract: The present disclosure relates to recombinant adeno-associated virus (AAV) vector serotype, wherein the capsid protein of AAV serotypes is mutated at single or multiple sites. The disclosure further relates to an improved transduction efficiency of these mutant AAV serotypes. The AAV serotypes disclosed are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10. The instant disclosure relates to nucleotide sequences, recombinant vector, methods and kit thereof.Type: ApplicationFiled: May 2, 2013Publication date: June 12, 2014Inventors: SANGEETHA HAREENDRAN, NISHANTH GABRIEL, DWAIPAYAN SEN, RUPALI GADKARI, SUDHA GOVINDARAJAN, NARAYANA SWAMY SRINIVASAN, ALOK SRIVASTAVA, GIRIDHARA RAO JAYANDHARAN, RUCHITA SELOT, BALAJI BALAKRISHNAN, AKSHAYA KRISHNAGOPAL
-
Publication number: 20140161777Abstract: The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain.Type: ApplicationFiled: February 13, 2014Publication date: June 12, 2014Applicant: University of Iowa Research FoundationInventors: Beverly L. Davidson, Yong Hong Chen